Market Overview - The A-share market shows a mixed performance with the Shanghai Composite Index closing at 3461.15, up by 0.18%, while the Shenzhen Component Index increased by 1.17% to 10534.58 [2][3] - The total market capitalization of the Shanghai Composite Index is 6718.87 billion, with a price-to-earnings (PE) ratio of 12.38 and a price-to-book (PB) ratio of 1.28 [3] Economic Indicators - The June China Warehousing Index stands at 51%, indicating continued expansion in the warehousing sector, with key sub-indices showing improvement [15][16] - The People's Bank of China conducted a 572 billion yuan reverse repurchase operation, with a rate of 1.40%, resulting in a net withdrawal of 4521 billion yuan on that day [17][18] - The Caixin China Services PMI for June recorded at 50.6, reflecting a slight decline from May, indicating a slowdown in the services sector [19] Industry Dynamics - In June 2025, 147 domestic game licenses were issued, marking a 17-game increase from May and a 43-game increase year-on-year, indicating a rise in approval efficiency [28][29] - The CMI index for June 2025 is reported at 105.15, showing a year-on-year increase of 5.09% but a month-on-month decrease of 11.99%, suggesting short-term pressure in the domestic engineering machinery market [30][31] - Wind and solar power generation utilization rates fell below 95% in May, with wind utilization at 93.2% and solar at 94.2%, indicating potential challenges in renewable energy consumption [32][34] Company Updates - DiZhe Pharmaceutical (688192.SH) received FDA approval for its drug Shuwotai, marking it as the first globally approved innovative drug for a specific type of lung cancer [35][36] - Warner Pharmaceutical (688799.SH) announced that its subsidiary received approval for the listing of a raw material drug, enhancing its product line and competitive edge [37][38]